Phathom Pharmaceuticals, Inc. (PHAT) is a publicly traded company in the Unknown sector. Across all available filings, 22 corporate insiders have executed 247 transactions totaling $158.4M, demonstrating a bearish sentiment with -$67.7M in net insider flow. The most recent transaction on Jan 21, 2026 involved a transaction of 776 shares valued at $10.6K.
No significant insider buying has been recorded for PHAT in the recent period.
No significant insider selling has been recorded for PHAT in the recent period.
Based on recent SEC filings, insider sentiment for PHAT is bearish with an Insider Alignment Score of 29/100 and a net flow of -$67.7M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Phathom Pharmaceuticals, Inc. (PHAT) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 22 insiders are actively trading PHAT stock, having executed 247 transactions in the past 90 days. The most active insider is Pharmaceutical Co Ltd Takeda (Executive), who has made 53 transactions totaling $58.5M.
Get notified when executives and directors at PHAT file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 21, 2026 | Charles Breedlove Robert | Principal Accounting Officer | Payment | 776 | $13.61 | $10.6K | |
| Jan 13, 2026 | Parikh Asit | Executive | Option Exercise | 8,750 | $N/A | $0 | |
| Jan 13, 2026 | Parikh Asit | Executive | Option Exercise | 8,750 | $10.30 | $90.1K | |
| Jan 2, 2026 | Narula Sanjeev | Chief Financial & Bus. Officer | Award | 42,848 | $N/A | $0 | C-Suite |
| Jan 2, 2026 | Narula Sanjeev | Chief Financial & Bus. Officer | Award | 82,715 | $N/A | $0 | C-Suite |
| Jan 2, 2026 | Marie Cook Anne | Chief Legal Off. & Corp. Sec. | Award | 67,878 | $N/A | $0 | |
| Jan 2, 2026 | Marie Cook Anne | Chief Legal Off. & Corp. Sec. | Award | 75,345 | $N/A | $0 | |
| Jan 2, 2026 | L. Basta Steven | Executive | Award | 226,156 | $N/A | $0 | |
| Jan 2, 2026 | L. Basta Steven | Executive | Award | 251,034 | $N/A | $0 | |
| Dec 19, 2025 | Parikh Asit | Executive | Option Exercise | 8,750 | $10.30 | $90.1K | |
| Dec 18, 2025 | Charles Breedlove Robert | Executive | Payment | 230 | $16.28 | $3.7K | |
| Dec 17, 2025 | L. Basta Steven | Executive | Award | 62,038 | $N/A | $0 | |
| Dec 17, 2025 | L. Basta Steven | Executive | Payment | 31,502 | $15.36 | $483.9K | |
| Dec 17, 2025 | Marie Cook Anne | Executive | Award | 17,370 | $N/A | $0 | |
| Dec 17, 2025 | Marie Cook Anne | Executive | Payment | 7,703 | $15.36 | $118.3K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 160 | $113.1M | 57.4% |
Purchase(P) | 19 | $45.3M | 23.0% |
Conversion(C) | 3 | $36.0M | 18.3% |
Payment(F) | 6 | $1.9M | 1.0% |
Award(A) | 47 | $390.0K | 0.2% |
Exercise(M) | 6 | $260.3K | 0.1% |
Exercise (Options)(X) | 2 | $0 | 0.0% |
Gift(G) | 3 | $0 | 0.0% |
Other(J) | 1 | $0 | 0.0% |
Insider selling pressure at Phathom Pharmaceuticals, Inc. has increased, with 22 insiders executing 247 transactions across all time. Total sales of $113.1M significantly outpace purchases of $45.3M, resulting in a net outflow of $67.7M. This selling activity appears largely discretionary, which may warrant closer attention from investors.